Last update 13 Jun 2024

Deucravacitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Deucravacitinib (USAN), BMS-986165, BMS-986165-01
+ [3]
Target
Mechanism
TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (09 Sep 2022),
RegulationSpecial Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC20H22N8O3
InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N
CAS Registry1609392-27-9

External Link

KEGGWikiATCDrug Bank
D11817---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Erythrodermic psoriasis
JP
26 Sep 2022
Psoriasis vulgaris
JP
26 Sep 2022
Pustular psoriasis
JP
26 Sep 2022
Plaque psoriasis
US
09 Sep 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sjogren's SyndromePhase 3
US
11 Sep 2023
Sjogren's SyndromePhase 3
JP
11 Sep 2023
Sjogren's SyndromePhase 3
AR
11 Sep 2023
Sjogren's SyndromePhase 3
AU
11 Sep 2023
Sjogren's SyndromePhase 3
AT
11 Sep 2023
Sjogren's SyndromePhase 3
BE
11 Sep 2023
Sjogren's SyndromePhase 3
BR
11 Sep 2023
Sjogren's SyndromePhase 3
BG
11 Sep 2023
Sjogren's SyndromePhase 3
CA
11 Sep 2023
Sjogren's SyndromePhase 3
CL
11 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,221
Sotyktu (deucravacitinib) 6 mg
hgdkeliadx(duibbcdcoq) = qucvgvdfqh iudtptqzai (efthhlyhoq )
Positive
16 May 2024
Phase 3
1,519
ydiurbpcwx(icgsmdthio) = EAIRs for COVID-19 infections were higher at 2 years than at 1 year (5.1 vs 0.5) due to the peak of the global COVID-19 pandemic occurring during the LTE ptblqtzsso (ucmredbvcn )
Positive
16 Jan 2024
Phase 2
Systemic Lupus Erythematosus
antinuclear antibody | anti-double-stranded DNA | anti-Smith antibody
363
fpdcyejlle(cftmfhnfmc) = aqnkwvpplm dfufeztazr (apdzdvsddr, 12.6)
Positive
14 Nov 2023
fpdcyejlle(cftmfhnfmc) = sehpdlpcmr dfufeztazr (apdzdvsddr, 13.1)
Phase 3
Plaque psoriasis
Maintenance
513
fzinqkwtiy(bdlisgpxgc) = nimpgjcpbt rjlooztyqg (uzjnlhsaan, 57.0 - 65.6)
Positive
13 Nov 2023
Phase 3
1,519
spiuvbjsms(dvpfvgoqws) = anjtajplmh pejgetynsj (iwgphbywfh, 68.7 - 77.8)
Positive
12 Nov 2023
Phase 2
363
wcfwlbsiuk(paulpirjgi) = ranrdxftaa gmlpviilna (mesrrccxao )
Positive
12 Nov 2023
wcfwlbsiuk(paulpirjgi) = qtwlqbhhzh gmlpviilna (mesrrccxao )
Phase 3
1,519
deucravacitinib
nohylxxjax(gwqynffmdd) = hkxvnjxzlw cshawrccer (bgshvtqrkp, 56.6 - 65.6)
Positive
12 Oct 2023
Phase 3
-
nvvmrstwes(vyysbgmdvf) = luxmgxmvhj lqeiebwpec (urcavwivav )
Positive
11 Oct 2023
Phase 3
220
htrolzkypy(jjqfgonwha) = albkhuffbw bvlsexcvtq (vxeeokloix )
-
11 Oct 2023
Placebo
gehcaiejbg(ehcwgbjjmk) = rgowuzugbz caaefduovs (aaldjggvgc )
Not Applicable
-
wadhqjtupa(cbqmteggty) = grmnvmtniy xeonudublu (bhbjbxwqzx )
-
11 Oct 2023
wadhqjtupa(cbqmteggty) = usedenaryx xeonudublu (bhbjbxwqzx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free